
Opinion|Videos|April 8, 2024
Efficacy and Safety of Emerging Therapies
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































